Understanding immune changes in arthritis caused by cancer treatments
Characterization of Altered Immunity in Patients with Inflammatory Arthritis Induced by Immune Checkpoint Inhibitor Therapy
This study is looking at how a cancer treatment called immune checkpoint inhibitors might cause joint pain and inflammation in some patients, and it aims to understand how the immune system, especially certain immune cells, is involved in this process to help improve care for those affected.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Yale University NIH-funded |
| Lab location | 1 site (New Haven, United States) |
| Project ID | NIH-10892882 on NIH RePORTER |
What this research studies
This research investigates how immune checkpoint inhibitor therapy, a treatment for advanced cancer, can lead to inflammatory arthritis in patients. The principal investigator, Dr. Sang Kim, aims to explore the immune system's response, particularly focusing on T cells and their role in this condition. By utilizing advanced genomic technologies, the study will analyze the biological markers and immune signatures in patients experiencing arthritis as a side effect of their cancer therapy. This research could provide insights into managing and preventing these adverse effects for better patient outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients receiving immune checkpoint inhibitors for advanced cancer who are experiencing symptoms of inflammatory arthritis.
Not a fit: Patients who are not undergoing immune checkpoint inhibitor therapy or do not have arthritis as a side effect may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved strategies for managing arthritis in patients undergoing cancer treatment.
How similar studies have performed: Other research has shown promising results in understanding immune-related adverse events in cancer therapies, indicating that this approach has potential for success.
Where this research is happening
New Haven, United States
- Yale University — New Haven, United States (Active)
Researchers
- Principal investigator: Kim, Sang Taek — Yale University
- Study coordinator: Kim, Sang Taek
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.